Investors & Media

Built by ElevateBio — the future of cell and gene therapy.

// Investors & Media

Corporate Profile

ElevateBio^® is a technology-driven company powering the creation of life-transforming cell and gene therapies. The company’s integrated model, combining R&D platforms and cGMP manufacturing, unifies groundbreaking technologies forging the missing link between discovery and widespread delivery of cell and gene therapies. Working with leading biopharma and academic partners, ElevateBio’s team of scientists, drug developers, and company builders are transforming the cell and gene therapy industry and are changing the future of medicine.

News, Media, & Presentations

Press Releases

All Press

// May 12, 2025

ElevateBio Appoints Ger Brophy, Ph.D., as Interim Chief Executive Officer and Member of the Board of Directors

Read More about ElevateBio Appoints Ger Brophy, Ph.D., as Interim Chief Executive Officer and Member of the Board of Directors

// April 28, 2025

ElevateBio Announces Presentations at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

Read More about ElevateBio Announces Presentations at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

// April 28, 2025

ElevateBio Announces Transition of David Hallal to Executive Chairman of the Board of Directors

Read More about ElevateBio Announces Transition of David Hallal to Executive Chairman of the Board of Directors

// March 10, 2025

ElevateBio Collaborates with AWS to Broaden the Potential of CRISPR Gene Editing Therapies with Generative AI

Read More about ElevateBio Collaborates with AWS to Broaden the Potential of CRISPR Gene Editing Therapies with Generative AI

// February 24, 2025

ElevateBio Announces Compelling Preclinical Data Demonstrating the Potential of LETI-101 as a Treatment for Huntington’s Disease

Read More about ElevateBio Announces Compelling Preclinical Data Demonstrating the Potential of LETI-101 as a Treatment for Huntington’s Disease

// January 9, 2025

ElevateBio to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Read More about ElevateBio to Present at the 43rd Annual J.P. Morgan Healthcare Conference

// November 4, 2024

ElevateBio Appoints Amy Pooler Ph.D., as Senior Vice President, Research and Development

Read More about ElevateBio Appoints Amy Pooler Ph.D., as Senior Vice President, Research and Development

// October 16, 2024

ElevateBio Announces Advancements of its Proprietary Lipid Nanoparticle (LNP) Delivery Platform with Liver Targeting and De-Targeting Potential

Read More about ElevateBio Announces Advancements of its Proprietary Lipid Nanoparticle (LNP) Delivery Platform with Liver Targeting and De-Targeting Potential

// May 14, 2024

ElevateBio Announces New U.S. Patents for Lead Life Edit CRISPR Systems and Adenine Deaminases Enabling Advanced Gene Editing Techniques

Read More about ElevateBio Announces New U.S. Patents for Lead Life Edit CRISPR Systems and Adenine Deaminases Enabling Advanced Gene Editing Techniques

// April 22, 2024

ElevateBio Announces Presentations at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

Read More about ElevateBio Announces Presentations at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

// January 8, 2024

ElevateBio to Highlight Growth of its Genetic Medicine Business Driven By Gene Editing and Manufacturing Partnerships at the 42nd Annual J.P. Morgan Healthcare Conference

Read More about ElevateBio to Highlight Growth of its Genetic Medicine Business Driven By Gene Editing and Manufacturing Partnerships at the 42nd Annual J.P. Morgan Healthcare Conference

// September 26, 2023

Kyverna Therapeutics and ElevateBio to Advance Kyverna’s Ingenui-T Cell Therapy Manufacturing

Read More about Kyverna Therapeutics and ElevateBio to Advance Kyverna’s Ingenui-T Cell Therapy Manufacturing

// May 24, 2023

ElevateBio Announces $401 Million Series D Financing to Further Accelerate Growth

Read More about ElevateBio Announces $401 Million Series D Financing to Further Accelerate Growth

// May 24, 2023

Novo Nordisk and Life Edit Therapeutics Establish Multi-Target Collaboration to Discover and Develop Gene Editing Therapies for Rare and Cardiometabolic Diseases

Read More about Novo Nordisk and Life Edit Therapeutics Establish Multi-Target Collaboration to Discover and Develop Gene Editing Therapies for Rare and Cardiometabolic Diseases

// May 15, 2023

ElevateBio Announces Presentations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting Highlighting Optimization of Processes for Viral Vector Production

Read More about ElevateBio Announces Presentations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting Highlighting Optimization of Processes for Viral Vector Production

// April 25, 2023

Life Edit Therapeutics to Present Data Demonstrating Therapeutic Potential of its Novel Gene Editing Platform

Read More about Life Edit Therapeutics to Present Data Demonstrating Therapeutic Potential of its Novel Gene Editing Platform

// March 7, 2023

ElevateBio Appoints Heidi L. Wagner, J.D., as Global Head of Government Affairs

Read More about ElevateBio Appoints Heidi L. Wagner, J.D., as Global Head of Government Affairs

// February 22, 2023

Moderna and Life Edit Therapeutics Enter Strategic Collaboration to Accelerate the Development of Novel In Vivo Gene Editing Therapies

Read More about Moderna and Life Edit Therapeutics Enter Strategic Collaboration to Accelerate the Development of Novel In Vivo Gene Editing Therapies

// January 5, 2023

ElevateBio to Present at the 41st Annual J.P. Morgan Healthcare Conference

Read More about ElevateBio to Present at the 41st Annual J.P. Morgan Healthcare Conference

// November 15, 2022

ElevateBio and Affini-T Therapeutics Announce Partnership to Advance Affini-T’s T Cell Therapy Programs Targeting Core Oncogenic Drivers

Read More about ElevateBio and Affini-T Therapeutics Announce Partnership to Advance Affini-T’s T Cell Therapy Programs Targeting Core Oncogenic Drivers

// November 3, 2022

ElevateBio BaseCamp Unveils its LentiPeak™ Lentiviral Vector Platform

Read More about ElevateBio BaseCamp Unveils its LentiPeak™ Lentiviral Vector Platform

// August 25, 2022

ElevateBio and the University of Pittsburgh Announce Creation of Pitt BioForge BioManufacturing Center at Hazelwood Green to Accelerate Cell and Gene Therapy Innovation

Read More about ElevateBio and the University of Pittsburgh Announce Creation of Pitt BioForge BioManufacturing Center at Hazelwood Green to Accelerate Cell and Gene Therapy Innovation

// August 23, 2022

ElevateBio Partners with the California Institute for Regenerative Medicine to Accelerate the Development of Regenerative Medicines

Read More about ElevateBio Partners with the California Institute for Regenerative Medicine to Accelerate the Development of Regenerative Medicines

// August 4, 2022

ElevateBio Announces the Formation of a New Company with George Daley, M.D., Ph.D., and Boston Children’s Hospital to Develop iPSC-Derived Allogeneic Immune Therapies

Read More about ElevateBio Announces the Formation of a New Company with George Daley, M.D., Ph.D., and Boston Children’s Hospital to Develop iPSC-Derived Allogeneic Immune Therapies

// June 2, 2022

ElevateBio Announces Jill M. Mooney, Ph.D., Joins as Senior Vice President of Research and Development

Read More about ElevateBio Announces Jill M. Mooney, Ph.D., Joins as Senior Vice President of Research and Development

// May 4, 2022

ElevateBio Announces Presentation on Lentiviral Vector Platform at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Read More about ElevateBio Announces Presentation on Lentiviral Vector Platform at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

// January 6, 2022

ElevateBio to Present at the 40th Annual J.P. Morgan Healthcare Conference

Read More about ElevateBio to Present at the 40th Annual J.P. Morgan Healthcare Conference

// November 15, 2021

ElevateBio Announces Issuance of U.S. Patent Providing Protection for RNA-Guided Nucleases Identified through its Life Edit Gene Editing Platform

Read More about ElevateBio Announces Issuance of U.S. Patent Providing Protection for RNA-Guided Nucleases Identified through its Life Edit Gene Editing Platform

// October 27, 2021

ElevateBio Supercharges Gene Editing and Therapeutic Product Development Capabilities Through Acquisition of Life Edit Therapeutics

Read More about ElevateBio Supercharges Gene Editing and Therapeutic Product Development Capabilities Through Acquisition of Life Edit Therapeutics

// June 29, 2021

Boston Children’s Hospital and ElevateBio Announce Five-Year Cell and Gene Therapy Collaboration

Read More about Boston Children’s Hospital and ElevateBio Announce Five-Year Cell and Gene Therapy Collaboration

// June 10, 2021

ElevateBio Announces Margo Roberts, Ph.D. Joins as Scientific Advisor for Company’s Immunotherapy Platform Expansion

Read More about ElevateBio Announces Margo Roberts, Ph.D. Joins as Scientific Advisor for Company’s Immunotherapy Platform Expansion

// April 27, 2021

ElevateBio’s BaseCamp Selected as the 2021 Facility of the Year Award Category Winner for Operational Excellence by the International Society for Pharmaceutical Engineering

Read More about ElevateBio’s BaseCamp Selected as the 2021 Facility of the Year Award Category Winner for Operational Excellence by the International Society for Pharmaceutical Engineering

// March 18, 2021

ElevateBio Announces Chief Scientific Officer of Regenerative Medicine, Melissa Carpenter, PhD, Elected to the International Society for Stem Cell Research Board of Directors

Read More about ElevateBio Announces Chief Scientific Officer of Regenerative Medicine, Melissa Carpenter, PhD, Elected to the International Society for Stem Cell Research Board of Directors

// March 15, 2021

ElevateBio Scales Disruptive Cell and Gene Therapy Business Model with $525 Million Series C Financing

Read More about ElevateBio Scales Disruptive Cell and Gene Therapy Business Model with $525 Million Series C Financing

// January 19, 2021

ElevateBio Announces Andrew Sandford Joins as President of ElevateBio BaseCamp

Read More about ElevateBio Announces Andrew Sandford Joins as President of ElevateBio BaseCamp

// January 8, 2021

ElevateBio to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

Read More about ElevateBio to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

// January 8, 2021

ElevateBio to Present at the 39th Annual J.P. Morgan Healthcare Conference

Read More about ElevateBio to Present at the 39th Annual J.P. Morgan Healthcare Conference

// January 8, 2021

39th Annual J.P. Morgan Healthcare Conference

Read More about 39th Annual J.P. Morgan Healthcare Conference

// December 6, 2020

ElevateBio’s HighPassBio Presents on Novel T Cell Receptor Cell Therapy for Leukemia Relapse at 62nd Annual ASH Meeting

Read More about ElevateBio’s HighPassBio Presents on Novel T Cell Receptor Cell Therapy for Leukemia Relapse at 62nd Annual ASH Meeting

// November 30, 2020

Piper Sandler 32nd Annual Virtual Healthcare Conference

Read More about Piper Sandler 32nd Annual Virtual Healthcare Conference

// November 16, 2020

ElevateBio and AgBiome Announce LifeEDIT Will Join ElevateBio’s Portfolio of Innovative Cell and Gene Therapy Companies

Read More about ElevateBio and AgBiome Announce LifeEDIT Will Join ElevateBio’s Portfolio of Innovative Cell and Gene Therapy Companies

// October 28, 2020

Morgan Stanley 18th Annual Global Healthcare Conference

Read More about Morgan Stanley 18th Annual Global Healthcare Conference

// August 25, 2020

ElevateBio to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

Read More about ElevateBio to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

// May 26, 2020

ElevateBio to Present at the Jefferies Virtual Healthcare Conference

Read More about ElevateBio to Present at the Jefferies Virtual Healthcare Conference

// March 30, 2020

ElevateBio Closes $170 Million Series B Financing

Read More about ElevateBio Closes $170 Million Series B Financing

// March 26, 2020

European Medicines Agency Grants Orphan Drug Designation to AlloVir’s Viralym-M, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy

Read More about European Medicines Agency Grants Orphan Drug Designation to AlloVir’s Viralym-M, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy

// March 23, 2020

AlloVir Expands Its Research Collaboration with Baylor College of Medicine to Discover and Develop Allogeneic, Off-the-Shelf, Virus-Specific T-Cell Therapies for COVID-19

Read More about AlloVir Expands Its Research Collaboration with Baylor College of Medicine to Discover and Develop Allogeneic, Off-the-Shelf, Virus-Specific T-Cell Therapies for COVID-19

// March 5, 2020

ElevateBio Appoints Kareem Reda as Chief Business Officer

Read More about ElevateBio Appoints Kareem Reda as Chief Business Officer

// February 19, 2020

AlloVir to Present at the SVB Leerink 9th Annual Global Healthcare Conference

Read More about AlloVir to Present at the SVB Leerink 9th Annual Global Healthcare Conference

// February 12, 2020

AlloVir Receives the European Medicines Agency PRIME Designation for Viralym-M, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy

Read More about AlloVir Receives the European Medicines Agency PRIME Designation for Viralym-M, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy

// December 9, 2019

ElevateBio Appoints Melissa K. Carpenter, Ph.D., as Chief Scientific Officer of Regenerative Medicine

Read More about ElevateBio Appoints Melissa K. Carpenter, Ph.D., as Chief Scientific Officer of Regenerative Medicine

// October 1, 2019

ElevateBio Launches HighPassBio to Advance Novel Targeted T Cell Immunotherapies with Technology from Fred Hutchinson Cancer Research

Read More about ElevateBio Launches HighPassBio to Advance Novel Targeted T Cell Immunotherapies with Technology from Fred Hutchinson Cancer Research

// September 10, 2019

Phase I Study of “Off-The-Shelf” Virus-Specific T Cells Published in BLOOD ADVANCES

Read More about Phase I Study of “Off-The-Shelf” Virus-Specific T Cells Published in BLOOD ADVANCES

// July 25, 2019

Massachusetts General Hospital and ElevateBio Announce a 10-Year Alliance Agreement to Utilize ElevateBio BaseCamp to Manufacture Innovative Cell and Gene Therapies

Read More about Massachusetts General Hospital and ElevateBio Announce a 10-Year Alliance Agreement to Utilize ElevateBio BaseCamp to Manufacture Innovative Cell and Gene Therapies

// June 11, 2019

AlloVir Announces Viralym-M Granted Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Hemorrhagic Cystitis Caused by BK Virus in Adults and Children Following Allogeneic HSCT

Read More about AlloVir Announces Viralym-M Granted Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Hemorrhagic Cystitis Caused by BK Virus in Adults and Children Following Allogeneic HSCT

// May 22, 2019

ElevateBio announces that Allovir joins its portfolio of highly innovative cell and gene therapy companies

Read More about ElevateBio announces that Allovir joins its portfolio of highly innovative cell and gene therapy companies

// May 13, 2019

ElevateBio Launches to Create and Operate a Portfolio of Highly Innovative Cell and Gene Therapy Companies

Read More about ElevateBio Launches to Create and Operate a Portfolio of Highly Innovative Cell and Gene Therapy Companies

Events & Presentations

All Events & Presentations

Elevated Insights

All Insights

ElevateBio’s Next-Generation Sequencing Core: Meeting the Challenges of Cost, Time and Data Quality with Expertise and Collaboration

By Adriana Geldart, Ph.D., Senior Director, Next-Generation Sequencing, ElevateBio

View Insight

Publications

All Publications

// February 4, 2025 | Cell & Gene

Accelerating Innovative Cell Therapy Development Through Phase-Appropriate Potency Control

Deb Bhattacharya, Ph.D. and Cindy Riggins, Ph.D.

// May 23, 2024 | Cell and Gene Therapy

Outsourced Pharma Capacity Update May 2024

Debaditya Bhattacharya, Ph.D. VP, Analytical Development and Miranda Williams Scientist I, Analytical Development discuss BaseCamp’s analytical capabilities and more in a recorded webcast.

// February 28, 2023 | The Long Run

A Life in Biotech & the Cell Therapy Wave: David Hallal on The Long Run

This episode was recorded in person at the JP Morgan Healthcare Conference in San Francisco. Biotech history buffs will especially enjoy the first half, where he talks about what pharmaceutical sales was like and what it was like to work at Amgen in the early days.

// October 12, 2022 | Biotech 2050 Podcast

A New Vision for Cell and Gene Therapy, Andrew Sandford & Michael Paglia, ElevateBio BaseCamp

Andrew Sandford and Michael Paglia are the President and COO, respectively, of ElevateBio BaseCamp, a cell and gene therapy technology company powering transformative therapies. They join us from the company’s manufacturing facilities in Waltham, Massachusetts, for a discussion about the landscape of company creation in the cell and gene therapy space and how ElevateBio is helping companies bring innovation and therapeutics to clinics and patients to help treat and cure diseases.

// July 12, 2022 | Ori Spotlight

Investors & Media

Corporate Profile

News, Media, & Presentations

Press Releases

Events & Presentations

Elevated Insights

Publications

Footer